Highlights

• FY2026 sales Revenue was about $2.34 billion, up 2% in constant currency but down 1% on a reported basis.

• Underlying net profit fell 22% to $322.4 million, from $414.5 million in FY2025, landing at the top of revised guidance.

• Statutory net profit fell to $147.3 million after $109.1 million of non-cash Investment writedowns, mainly tied to Epiminder.

• The board cut the final Dividend to $1.30 per share from $2.15, taking the full-year payout to about $3.45 versus $4.30 in FY2025.

• FY2027 guidance points to underlying net profit of $330 million to $350 million, implying a return to growth.

• A stronger Australian dollar could reduce FY2027 profit by roughly 10% versus FY2026 average rates.

Cochlear, the global leader in hearing implants, has been a conspicuous laggard in the recent revival of ASX healthcare stocks. Its FY2026 result confirmed why: Underlying Profit fell 22 per cent, the dividend was cut and statutory Earnings were hit by sizeable writedowns. The company nonetheless landed at the top of its downgraded guidance range and pointed to a return to growth in FY2027, framing the year as a reset rather than a structural decline.

Latest Developments

For the year to 30 June 2026, Cochlear reported sales revenue of about $2.34 billion, up 2 per cent in constant currency but down 1 per cent on a reported basis. Underlying net profit came in at $322.4 million, down 22 per cent from FY2025's $414.5 million, though at the upper end of the revised $290 million to $330 million guidance the company had flagged earlier in the year.

Statutory net profit fell far more steeply, to $147.3 million, after $109.1 million of non-cash investment writedowns, primarily tied to neural-monitoring investee Epiminder, and around $66 million of cloud-computing costs. The board cut the final dividend to $1.30 per share, down from $2.15 a year earlier, taking the full-year payout to about $3.45 against $4.30 in FY2025.

What the Numbers Show

The result lays bare the pressures of a year in which modest revenue growth could not offset cost investment and a higher effective tax position. Reported revenue actually slipped in Australian-dollar terms, and the gap between underlying and statutory profit highlights the impact of the Epiminder writedown and technology spending on the bottom line.

Encouragingly, management guided to FY2027 underlying net profit of $330 million to $350 million, implying a return to growth, on low single-digit constant-currency revenue growth. That guidance assumes an Australian dollar around US 70 cents, and the company warned a stronger currency could reduce profit by roughly 10 per cent versus FY2026 average rates.

The lower full-year payout of about $3.45 is notable for a company that had built a long record of steadily rising dividends. Cochlear has historically targeted a payout of around 70 per cent of underlying net profit, so the reduction is largely a mechanical consequence of the lower earnings base rather than a change in policy, but it nonetheless dents one of the reasons income-oriented investors had held the stock.

What Could Drive the Stock Next

New-product momentum is the core of the recovery case. Cochlear has been rolling out its latest sound processors and implant systems, and a healthy upgrade and services cycle within its large installed base provides a Recurring Revenue stream less exposed to surgical scheduling.

Demographics remain a structural tailwind, with ageing populations and low penetration of implantable hearing solutions in adults. Delivery on the FY2027 profit guidance would be the clearest signal that FY2026 was a trough rather than a new baseline.

Key Risks to Watch

Currency is an outsized risk given Cochlear earns most revenue offshore; a stronger Australian dollar directly erodes reported profit. Elective-surgery capacity, hospital access and reimbursement settings in key markets also influence implant volumes.

Competition in cochlear and acoustic implants is intensifying, and the Epiminder writedown is a reminder that the company's venture and adjacency investments carry risk. Any slippage against the FY2027 guidance would test patience after a disappointing year.

Investor Takeaway

Cochlear's FY2026 was a step backwards, not the comeback some of its healthcare peers enjoyed, with lower profit, a trimmed dividend and material writedowns. The company's scale, installed base and guided return to growth in FY2027 keep the long-term story intact, but investors will want evidence that the reset delivers before crediting Cochlear with a genuine recovery.

This article is general information only and does not constitute financial or investment advice.